Liquidia Corporation LQDA Yutrepia — Program Expenses

Similar metrics at other companies

ARVNOther programs — Program-specific external expense

$2.6M+52.9%

NUV

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

PRAXRelutrigine — Program-specific expenses

$13.98M+33.0%

PRAXUlixacaltamide — Program-specific expenses

$13.3M-27.7%

PRAXVormatrigine — Program-specific expenses

$12.88M-28.3%

PRAXElsunersen — Program-specific expenses

$8.14M+518%

FAQ

What is Liquidia Corporation's yutrepia — program expenses?

Liquidia Corporation (LQDA) reported yutrepia — program expenses of $15.89M in Q1 2026.

How has Liquidia Corporation's yutrepia — program expenses changed year-over-year?

Liquidia Corporation's yutrepia — program expenses increased by 62.8% year-over-year, from $9.76M to $15.89M.

What is the long-term trend for Liquidia Corporation's yutrepia — program expenses?

Over 2 years (2023 to 2025), Liquidia Corporation's yutrepia — program expenses has grown at a 53.6% compound annual growth rate (CAGR), from $23.49M to $55.44M.

What does yutrepia — program expenses mean?

This metric represents the direct research, development, and commercialization costs specifically allocated to the Yutrepia product line. It captures the investment intensity required to advance the product through clinical trials, regulatory approval, and market launch phases. Monitoring this helps investors assess the capital commitment dedicated to the company's primary therapeutic asset.